頁籤選單縮合
題 名 | 選用帶狀疱疹疫苗新策略=New Insights of Herpes Zoster Vaccines |
---|---|
作 者 | 蔡憶萱; 楊璦瑜; | 書刊名 | 藥學雜誌 |
卷 期 | 35:4=141 2019.12[民108.12] |
頁 次 | 頁36-40 |
分類號 | 418.293 |
關鍵詞 | 帶狀疱疹疫苗; Recombinant zoster vaccine; Zoster vaccine live; Shingrix; |
語 文 | 中文(Chinese) |
中文摘要 | 帶狀疱疹疫苗已被證實可降低帶狀疱疹的發生風險及改善帶狀疱疹後神經痛。疫 苗接種可減少高齡病人的疾病負擔及併發症。活性減毒帶狀疱疹疫苗被核准用於預防 ≥ 50 歲免疫功能正常的成人帶狀疱疹。然而數個活性減毒疫苗的臨床試驗證實其在高 齡族群中效果較差,且療效隨著時間的推移而減弱。Shingrix 是新型帶狀疱疹疫苗,為 非活性重組次單位疫苗於2017年10月獲 FDA 批准用於預防帶狀疱疹。本文將論述兩 種疫苗的療效與安全性及美國疫苗接種諮詢委員會最新發布的帶狀疱疹接種建議事項。 |
英文摘要 | Herpes zoster (HZ) vaccination has been shown to decreases the risk of developing herpes zoster and postherpetic neuralgia. Vaccination against HZ has reduced HZ disease burden and complications in older adults. Zoster Vaccine Live (ZVL), is licensed for the prevention of herpes zoster in immunocompetent adults aged ≥ 50 years. However several clinical trials of ZVL has been shown to be less effective in older age groups and its efficacy wanes over time. Shingrix, the new herpes zoster vaccine is an adjuvanted recombinant subunit vaccine that was approved by the Food and Drug Administration in October 2017 for the prevention of herpes zoster. The purpose of this article is to review the efficacy, and safety data for two types of HZ vaccines, and the Advisory Committee on Immunization Practices (ACIP) recommending for the prevention of herpes zoster. |
本系統中英文摘要資訊取自各篇刊載內容。